Paritaprevir
Structural formula | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
General | ||||||||||||||||
Non-proprietary name | Paritaprevir | |||||||||||||||
other names |
|
|||||||||||||||
Molecular formula | C 40 H 43 N 7 O 7 S 1 | |||||||||||||||
External identifiers / databases | ||||||||||||||||
|
||||||||||||||||
Drug information | ||||||||||||||||
ATC code | ||||||||||||||||
properties | ||||||||||||||||
Molar mass | 765.88 g mol −1 | |||||||||||||||
safety instructions | ||||||||||||||||
|
||||||||||||||||
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions . |
Paritaprevir (formerly known as ABT-450 ) is a Acylsulfonamidinhibitor the NS3-4A- serine protease that of Abbott Laboratories for the treatment of hepatitis C is established. When given in combination with ritonavir and ribavirin for 12 weeks, genotype 1 hepatitis C virus is 95% eliminated after 24 weeks.
Paritaprevir is part of the combination preparations Viekira Pak and Technivie .
Individual evidence
- ↑ This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.
- ↑ Seng-Lai Tan, Yupeng He (Ed.): Hepatitis C: antiviral drug discovery and development . Caister academic press, Norfolk 2011, ISBN 9781904455783 , p. 210 ( Accessed April 28, 2014).
- ↑ Donald Jensen, Nancy Reau (ed.) Hepatitis C . Oxford University Press, New York 2013, ISBN 9780199844296 , p. 144 ( Accessed April 28, 2014).
- ↑ Abbott Announces Phase 3 Hepatitis C Program Details . In: Abbott company website . Abbott Laboratories. Retrieved April 28, 2014.
- ↑ Kris V. Kowdley, Eric Lawitz, Fred Poordad, Daniel E. Cohen, David R. Nelson, Stefan Zeuzem, Gregory T. Everson, Paul Kwo, Graham R. Foster, Mark S. Sulkowski, Wangang Xie, Tami Pilot-Matias , George Liossis, Lois Larsen, Amit Khatri, Thomas Podsadecki, Barry Bernstein: Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1 . In: New England Journal of Medicine . 370, No. 3, 2014, pp. 222-232. doi : 10.1056 / NEJMoa1306227 .
- ↑ TECHNIVIE ™ (ombitasvir, paritaprevir and ritonavir) tablets, for oral use. Full prescribing information . AbbVie Inc., North Chicago, IL 60064. Archived from the original on January 19, 2019. Retrieved July 28, 2015.